ClinicalTrials.Veeva

Menu

COPD Co-infection With Tuberculosis on Th17 Cell Differentiation

P

Peking University

Status

Completed

Conditions

Chronic Obstructive Pulmonary Disease
Tuberculosis Infection

Treatments

Other: No intervention

Study type

Observational

Funder types

Other

Identifiers

NCT04966052
M2017390

Details and patient eligibility

About

This project will observe and follow up the changes of pulmonary function and CT in patients with smoking combined with pulmonary tuberculosis, and measure the ratio of Th1 cells, Th17 cells, macrophages and neutrophils and the secretion of factors such as TNF-α, IFN-γ and IL-17 in pulmonary blood and alveolar lavage fluid.

Full description

Chronic obstructive pulmonary disease (COPD) and tuberculosis are major global health problems, and acquired and acquired immunity play an important role in COPD and tuberculosis, and there is an interaction between COPD and tuberculosis, but the exact mechanism is not clear. Pre-existing TB infection is an independent risk factor for COPD and can aggravate pulmonary function and increase hospitalization and mortality in COPD patients. In COPD patients, Th1 and Th17 cells are involved in the development of COPD and emphysema through activation of macrophages and recruitment of neutrophils, while matrix metalloproteinases (MMPs) of macrophage and neutrophil origin are involved in the formation of tuberculosis cavities, and cytokines such as TNF-α, IFN-γ, IL-17 are involved in the mechanism of their destruction, IL-17 restricts the expression of HIF-1α to inhibit the development of TB granulomas, and CT analysis revealed that combined TB exacerbates emphysema in COPD patients. The above evidence suggests that tuberculosis plays an important role in the formation of emphysema in COPD. In this project, we will observe and follow up the changes of pulmonary function and CT in patients with smoking combined with pulmonary tuberculosis, and examine the ratio of Th1 cells, Th17 cells, macrophages and neutrophils and the secretion of TNF-α, IFN-γ, and IL-17 in pulmonary blood and alveolar lavage fluid.

Enrollment

80 patients

Sex

All

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Clinical diagnosis of COPD
  • age ≧ 40

Exclusion criteria

  • Presence of other chronic respiratory diseases other than COPD, such as asthma, bronchiectasis, interstitial lung disease, etc.
  • History of chest and lung surgery.
  • History of malignancy.
  • Autoimmune disease.
  • Long-term oral glucocorticoids, immunosuppressants and inhaled glucocorticoids.
  • Mental abnormalities, cognitive impairment, inability to cooperate with pulmonary function and other tests.
  • Acute stage of infection, such as lung infection, urinary tract infection and gastrointestinal tract infection, etc.

Trial design

80 participants in 4 patient groups

COPD combined with TB group
Description:
COPD combined with pulmonary TB infection
Treatment:
Other: No intervention
COPD non-TB control group
Description:
COPD combined without pulmonary TB infection
TB non-COPD control group
Description:
pulmonary TB infection without COPD
Non-smoking non-TB control group
Description:
Non-smoking without pulmonary TB infection

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems